You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK)擬7.5億元收購上藥生物醫藥100%股份
格隆匯 05-27 19:02

格隆匯5月27日丨上海醫藥(02607.HK)公吿,公司於2021年5月27日與上海新先鋒訂立股權轉讓協議,據此,上海新先鋒同意將其持有的上藥生物醫藥100%的股權以人民幣7.5億元的對價(受限於國有資產監督管理部門的備案)轉讓予公司。 

收購完成後,公司將直接持有上藥生物醫藥100%的股權。上藥生物醫藥將成為公司的全資附屬公司,其財務業績將被納入公司合併財務報表範圍。

在“健康中國2030”戰略實施的背景下,公司緊抓機遇,堅定不移佈局創新轉型,工業板塊年研發投入額逐年創新高,“十四五”期間目標為研發投入達到工業銷售收入10%以上,並初步轉型成為以科技創新為驅動的研發型醫藥企業。隨着公司創新藥管線不斷豐富以及創新合作平台的科技成果加速轉化,公司需要進一步完善研發、孵化、中試、產業化等方面的創新平台。

考慮到上海市在創新藥研發方面的領先優勢,公司決定在上海市張江地區建設新的生物醫藥創新研發、孵化與產業化基地,匯聚創新人才、技術、項目、資本等資源,支撐下一輪的創新發展。上藥生物醫藥擁有的土地位於上海市浦東新區張江路92號,處於生物醫藥產業聚集的張江科學城的核心區域,主要聚焦治療性抗體、細胞治療、微生態、基因治療等領域,有利於打造國內生物醫藥板塊佈局齊全、技術領先的創新孵化與轉化平台。

本次收購將增強本公司的自主研發能力及創新能力,為本公司提供國際領先水準的研發環境及打造開放式研發公共服務平台。同時,依託本公司覆蓋全國的銷售及供應鏈網絡,本次收購將進一步加快本公司新上市藥品品種的增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account